YBYoung Bull
Menu
COMPANY WORKBOOK · BSX

Boston Scientific Corporation

Healthcare & Life Sciences · Medical Devices

$43.72+0.88%
35/100
Overall
MARKET CAP65.1B
FORWARD P/E13.14
PEG RATION/A
REVENUE GROWTH7.5%
OPERATING MARGIN22.9%
52W RANGE$42.63$104.98
ChartScoreRelative StrengthFinancialsThesisFiles
INTERACTIVE PRICE CHART

Trend and moving averages

RELATIVE PERFORMANCE

BSX versus SPY and SMH

Indexed to 100
LIVE MODEL SCORE

Cross-sectional ranking

Momentum17
Technicals10
Fundamentals56
Thematic Fit55

Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.

YOUNG BULL THESIS

Healthcare & Life Sciences

This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.

MODEL READ

Overall score: 34.5. Last ranked 2026-09-22.

QUARTERLY FUNDAMENTALS

Revenue and earnings power

TRAILING P/E18.19
PRICE / SALES3.10
EV / EBITDA13.56
BOOK VALUEN/A
GROSS MARGIN69.2%
PROFIT MARGIN17.5%
RETURN ON EQUITY15.3%
FREE CASH FLOW2.45B
COMPANY SNAPSHOT

What it does

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

PRIMARY SOURCES

Files and filings